Development Stage Phase III
Preclinical
Phase I
Phase II
Phase III
Approved
Phase III: Large-scale Efficacy
Tesofensine
Last updated: 1/23/2026 Last reviewed: 1/23/2026
At a Glance
Tesofensine is a small molecule investigated in obesity and neuropsychiatric contexts (often described as a monoamine reuptake inhibitor). Clinical benefit-risk depends on population and indication and requires careful primary-source review.
⚠️ Research Status: This dossier is an intake stub pending literature curation. It is not medical advice. Protocol/dosing guidance is intentionally not included.
Intake Notes (Unreviewed)
- Tags (from internal sheet): Focus; Weight Loss; Energy
- Reported adverse effects (unverified): constipation/diarrhea; dry mouth; headache; blood pressure changes; increased heart rate; insomnia; nausea
Mechanism of Action (TBD)
Often described as inhibiting reuptake of multiple monoamines (needs primary sources).
Evidence Summary
Low Confidence ReviewLiterature curation pending.
Key Studies
| Year | Type | Topic | Notes |
|---|---|---|---|
| 2008 | Clinical trial | Lancet study - 10.6% weight loss | PMID 19043376 |
| 2018 | Phase 3 | Viking Phase 3 study | - |
| 2023 | Regulatory | COFEPRIS Mexico approval | - |
Safety & Unknowns
- Cardiovascular parameters (heart rate/blood pressure) are frequently discussed and need citation-backed characterization.
- Reported adverse effects above are unverified and may not be complete.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added intake stub from compounds sheet |